423 related articles for article (PubMed ID: 25320633)
21. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
[TBL] [Abstract][Full Text] [Related]
22. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
Calin R; Hamimi C; Lambert-Niclot S; Carcelain G; Bellet J; Assoumou L; Tubiana R; Calvez V; Dudoit Y; Costagliola D; Autran B; Katlama C;
AIDS; 2016 Mar; 30(5):761-9. PubMed ID: 26730568
[TBL] [Abstract][Full Text] [Related]
23. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
Lam YM; McBride KL; Amin J; Cordery DV; Kelleher AD; Cooper DA; Koelsch KK
PLoS One; 2012; 7(3):e31990. PubMed ID: 22396745
[TBL] [Abstract][Full Text] [Related]
24. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
Hatano H; Hayes TL; Dahl V; Sinclair E; Lee TH; Hoh R; Lampiris H; Hunt PW; Palmer S; McCune JM; Martin JN; Busch MP; Shacklett BL; Deeks SG
J Infect Dis; 2011 Apr; 203(7):960-8. PubMed ID: 21402547
[TBL] [Abstract][Full Text] [Related]
25. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
[TBL] [Abstract][Full Text] [Related]
26. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial.
Katlama C; Lambert-Niclot S; Assoumou L; Papagno L; Lecardonnel F; Zoorob R; Tambussi G; Clotet B; Youle M; Achenbach CJ; Murphy RL; Calvez V; Costagliola D; Autran B;
AIDS; 2016 Jan; 30(2):221-30. PubMed ID: 26684819
[TBL] [Abstract][Full Text] [Related]
27. Anti-HIV Activity of Standard Combined Antiretroviral Therapy in Primary Cells Is Intensified by CCR5-Targeting Drugs.
Weichseldorfer M; Affram Y; Heredia A; Tagaya Y; Benedetti F; Zella D; Reitz M; Romerio F; Latinovic OS
AIDS Res Hum Retroviruses; 2020 Oct; 36(10):835-841. PubMed ID: 32623916
[TBL] [Abstract][Full Text] [Related]
28. Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.
Gutiérrez C; Hernández-Novoa B; Vallejo A; Serrano-Villar S; Abad-Fernández M; Madrid N; Díaz L; Moreno A; Dronda F; Zamora J; Muñoz-Fernández MA; Moreno S
AIDS; 2013 Aug; 27(13):2081-8. PubMed ID: 24384589
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
Massanella M; Esteve A; Buzón MJ; Llibre JM; Puertas MC; Gatell JM; Domingo P; Stevenson M; Clotet B; Martinez-Picado J; Blanco J;
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):152-60. PubMed ID: 23392458
[TBL] [Abstract][Full Text] [Related]
30. Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.
Massanella M; Ouchi D; Marfil S; Llibre JM; Puertas MC; Buzón MJ; Richman DD; Orna E; Stevenson M; Gatell JM; Domingo P; Negredo E; Martinez-Picado J; Clotet B; Blanco J
PLoS One; 2014; 9(12):e114142. PubMed ID: 25462535
[TBL] [Abstract][Full Text] [Related]
31. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
[TBL] [Abstract][Full Text] [Related]
32. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
[TBL] [Abstract][Full Text] [Related]
33. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
[TBL] [Abstract][Full Text] [Related]
34. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
Buzón MJ; Codoñer FM; Frost SD; Pou C; Puertas MC; Massanella M; Dalmau J; Llibre JM; Stevenson M; Blanco J; Clotet B; Paredes R; Martinez-Picado J
PLoS Pathog; 2011 Oct; 7(10):e1002314. PubMed ID: 22046128
[TBL] [Abstract][Full Text] [Related]
35. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
Yukl SA; Shergill AK; McQuaid K; Gianella S; Lampiris H; Hare CB; Pandori M; Sinclair E; Günthard HF; Fischer M; Wong JK; Havlir DV
AIDS; 2010 Oct; 24(16):2451-60. PubMed ID: 20827162
[TBL] [Abstract][Full Text] [Related]
36. Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir.
Abad-Fernández M; Cabrera C; García E; Vallejo A
J Clin Virol; 2014 Mar; 59(3):204-7. PubMed ID: 24457115
[TBL] [Abstract][Full Text] [Related]
37. Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.
Pallikkuth S; Sharkey M; Babic DZ; Gupta S; Stone GW; Fischl MA; Stevenson M; Pahwa S
J Virol; 2015 Dec; 90(6):2718-28. PubMed ID: 26676775
[TBL] [Abstract][Full Text] [Related]
38. Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy.
Wang X; Mink G; Lin D; Song X; Rong L
J Theor Biol; 2017 Mar; 416():16-27. PubMed ID: 28025011
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir.
Ouyang Z; Buzon MJ; Zheng L; Sun H; Yu XG; Bosch RJ; Mellors JW; Eron JJ; Gandhi RT; Lichterfeld M
Open Forum Infect Dis; 2015 Apr; 2(2):ofv045. PubMed ID: 26380343
[TBL] [Abstract][Full Text] [Related]
40. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
Hunt PW; Shulman NS; Hayes TL; Dahl V; Somsouk M; Funderburg NT; McLaughlin B; Landay AL; Adeyemi O; Gilman LE; Clagett B; Rodriguez B; Martin JN; Schacker TW; Shacklett BL; Palmer S; Lederman MM; Deeks SG
Blood; 2013 Jun; 121(23):4635-46. PubMed ID: 23589670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
